Clearmind Medicine (CMND) Share-based Compensation (2022 - 2026)
Clearmind Medicine (CMND) posted quarterly Share-based Compensation of $131252.0 for Q2 2026, down 43.36% year-over-year from $231722.0 in Q2 2025, and down 90.72% quarter-over-quarter from $1.4 million in Q1 2026.
Clearmind Medicine (CMND) Share-based Compensation (2022 - 2026) Analysis & Trends
Clearmind Medicine's Share-based Compensation history runs 5 years deep, the most recent figure standing at $131252.0 for Q2 2026.
- In Q2 2026, Share-based Compensation fell 43.36% year-over-year to $131252.0; the TTM figure through Apr 2026 stood at $1.7 million (up 35.09% YoY), while the FY2025 annual figure was $805890.0, down 19.32% from the prior year.
- Share-based Compensation for Q2 2026 stood at $131252.0, down from $1.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $1004.3 billion in Q3 2022, with the low at -$1004.3 billion in Q4 2022.
- The 5-year median for Share-based Compensation is $231722.0 (2025), against an average of $298784.8.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 100.0% in 2023, then surged 1019.69% in 2025.
- Clearmind Medicine's Share-based Compensation stood at -$1004.3 billion in 2022, then jumped by 100.0% to $505781.0 in 2023, then sank by 41.17% to $297544.0 in 2024, then plunged by 61.14% to $115640.0 in 2025, then gained by 13.5% to $131252.0 in 2026.
- Business Quant data shows CMND's Share-based Compensation at $131252.0 in Q2 2026, $1.4 million in Q1 2026, and $115640.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Clearmind Medicine | 520,887.91 | -13.07 Mn | - | 2.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 131,252.00 |
| Apr 30, 2026 | 131,252.00 |
| Jan 31, 2026 | 1.41 Mn |
| Jan 31, 2026 | 1.41 Mn |
| Oct 31, 2025 | 115,640.00 |
| Oct 31, 2025 | 115,640.00 |
| Jul 31, 2025 | 77,790.00 |
| Jul 31, 2025 | 77,790.00 |
| Apr 30, 2025 | 231,722.00 |
| Apr 30, 2025 | 231,722.00 |
| Jan 31, 2025 | 380,738.00 |
| Jan 31, 2025 | 380,738.00 |
| Oct 31, 2024 | 297,544.00 |
| Oct 31, 2024 | 297,544.00 |
| Jul 31, 2024 | 377,279.00 |
| Jul 31, 2024 | 377,279.00 |
| Apr 30, 2024 | 290,091.00 |
| Apr 30, 2024 | 290,091.00 |
| Jan 31, 2024 | 34,004.00 |
| Jan 31, 2024 | 34,004.00 |